OCGN Stock Pops on Key FDA News. Here’s What to Know.

InvestorPlace2021-12-10

Biopharmaceutical company Ocugen(NASDAQ:OCGN) announced today that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a human clinical ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

CHoe
2021-12-15
CHoe
Why
Dorcasnoobie
2021-12-10
Dorcasnoobie
[财迷]
Lichiun
2021-12-10
Lichiun
Like please, thank you!
- Lichiun:
  Like
- JeremyKok:
  hi. please like and comment back. thank you.
- Lichiun:
  Like
Albaakbert
2021-12-10
Albaakbert
Hock hock
HOCK
2021-12-10
HOCK
No escape when they manipulate ETFs in their favor. Just HODL and it will pop.
JCinvest
2021-12-10
JCinvest
Yeah

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1186120067?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-10 10:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186120067","market":"us","top_or_hot":-1,"title":"OCGN Stock Pops on Key FDA News. Here’s What to Know.","media":"InvestorPlace","content":"<div>\n<p>Biopharmaceutical company Ocugen(NASDAQ:OCGN) announced today that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a human clinical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/ocgn-stock-pops-on-key-fda-news-heres-what-to-know/\">网页链接</a>\n\n</div>\n","source":"lsy1606302653667","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OCGN Stock Pops on Key FDA News. Here’s What to Know.</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOCGN Stock Pops on Key FDA News. Here’s What to Know.\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-10 10:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/ocgn-stock-pops-on-key-fda-news-heres-what-to-know/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biopharmaceutical company Ocugen(NASDAQ:OCGN) announced today that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a human clinical ...</p>\n\n<a href=\"https://investorplace.com/2021/12/ocgn-stock-pops-on-key-fda-news-heres-what-to-know/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCGN","symbol_name":"Ocugen","start_time":0,"source_url":"https://investorplace.com/2021/12/ocgn-stock-pops-on-key-fda-news-heres-what-to-know/","article_id":"1186120067","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186120067","pubTimestamp":1639102922,"columns":[],"sourceInfo":{"source_id":"lsy1606302653667","name":"InvestorPlace"},"weMediaInfo":null,"summary":"Biopharmaceutical company Ocugen(NASDAQ:OCGN) announced today that the U.S. Food and Drug Administra","collect":0,"end_time":0,"defaultTopTitle":"investorplace.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCGN":"Ocugen"},"translate_title":"OCGN在美国食品和药物管理局的关键新闻上库存持久性有机污染物。以下是要知道的。","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9},"content_text":"Biopharmaceutical company Ocugen(NASDAQ:OCGN) announced today that the U.S. Food and Drug Administration (FDA) approved the company’s Investigational New Drug (IND) application for a human clinical trial of OCU400. OCU400 is a gene-therapy candidate targeting several degenerative eye diseases that severely impair vision. Despite the news, OCGN stock is down 6.3% today as investors seem reluctant to buy into the struggling med-tech company.\nShankar Musunuri, chief executive and co-founder of Ocugen, commented on the significance of this recent development.\n\n“We are delighted to advance OCU400 into clinical trials, which exemplifies our goal of offering new options to people with genetic diseases where none currently exist. … We’re collaborating with leading centers in eye care and have been vital partners to getting our trial launched and receive patients. With this final decision by the FDA, we are embarking on a new pathway of care through this innovative gene therapy.”\n\nThe news comes as a welcome change of pace for the company. Ocugen is perhaps best known for its Covid-19 vaccine Covaxin, which largely lags behind the competition. On Nov. 30, the FDA issued a hold on an approval application for late-stage clinical testing of its vaccine.\nOcugen represents just the North American side of the vaccine’s distribution. Meanwhile, Bharat Biotech, co-developer of the vaccine, has earned approval for use in 17 countries, including the company’s native India. This stands in stark contrast to Ocugen, who many investors believe is too little too late. Ocugen has come under fire for attempting to penetrate largely saturated Western markets as it pertains to vaccine options.\nWill this latest news shake things up for the struggling pharma company?\nOCU400: A Silver Lining for Struggling OCGN stock\nArguably, OCU400 is Ocugen’s main prize-horse going forward. Anticipation surrounding the company’s breakthrough gene-therapy programs has taken OCGN stock to the moon and back in the past few years. However, that anticipation has largely died down. With many estimating it could be years before such a therapy hits the market, combined with seemingly constant roadblocks for its vaccine candidate, OCGN stock has been on a cold streak for quite a while. Therefore, this news should come as a breath of fresh air for OCGN investors.\nPreliminary estimates see OCU400 being a completely novel solution to a series of retinal degenerative diseases. This year, the European Medicines Agency (EMA) even granted OCU400 a broad medical designation for two different optical diseases.\nWhile investors currently seem hesitant, hope isn’t lost yet. Positive developments of this nature can create the positive momentum necessary to bring the stock back from the dead.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":607802804,"gmtCreate":1639521427319,"gmtModify":1639521427391,"author":{"id":"3571622425597498","authorId":"3571622425597498","name":"CHoe","avatar":"https://static.tigerbbs.com/4cbccaeed1db5ce29ec7de0973a2565b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3571622425597498","authorIdStr":"3571622425597498"},"htmlText":"Why","listText":"Why","text":"Why","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/607802804","repostId":1186120067,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":605304917,"gmtCreate":1639108446357,"gmtModify":1639108858970,"author":{"id":"3568627166850888","authorId":"3568627166850888","name":"Dorcasnoobie","avatar":"https://static.tigerbbs.com/fcb2f4d29a8d87a5cbbe0eaf795e5613","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3568627166850888","authorIdStr":"3568627166850888"},"htmlText":"[财迷]&nbsp;","listText":"[财迷]&nbsp;","text":"[财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605304917","repostId":1186120067,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":605957394,"gmtCreate":1639104981218,"gmtModify":1639105766280,"author":{"id":"3568372592076919","authorId":"3568372592076919","name":"Lichiun","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3568372592076919","authorIdStr":"3568372592076919"},"htmlText":"Like please, thank you!","listText":"Like please, thank you!","text":"Like please, thank you!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/605957394","repostId":1186120067,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6927899,"gmtCreate":1639141632612,"gmtModify":1639141632639,"authorId":3568372592076919,"author":{"id":3568372592076919,"idStr":"3568372592076919","authorId":3568372592076919,"name":"Lichiun","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":605957394,"type":1,"supId":6926907,"prevId":0,"content":"Like","text":"Like","html":"Like"},{"id":6926907,"gmtCreate":1639134271096,"gmtModify":1639134271130,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":605957394,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":6923295,"gmtCreate":1639109331439,"gmtModify":1639109331529,"authorId":3568372592076919,"author":{"id":3568372592076919,"idStr":"3568372592076919","authorId":3568372592076919,"name":"Lichiun","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":605957394,"type":1,"supId":0,"prevId":0,"content":"Like","text":"Like","html":"Like"}],"langContent":"CN"},{"id":605955766,"gmtCreate":1639104805489,"gmtModify":1639104805895,"author":{"id":"3573197870935019","authorId":"3573197870935019","name":"Albaakbert","avatar":"https://static.tigerbbs.com/38fb1a202f211aaf65a6b491072b884f","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3573197870935019","authorIdStr":"3573197870935019"},"htmlText":"Hock hock","listText":"Hock hock","text":"Hock hock","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605955766","repostId":1186120067,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":605955833,"gmtCreate":1639104773836,"gmtModify":1639104774310,"author":{"id":"3574326262963990","authorId":"3574326262963990","name":"HOCK","avatar":"https://static.tigerbbs.com/88799e7ae4e69750fd2f85687a24a9e3","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3574326262963990","authorIdStr":"3574326262963990"},"htmlText":"No escape when they manipulate ETFs in their favor. Just HODL and it will pop.","listText":"No escape when they manipulate ETFs in their favor. Just HODL and it will pop.","text":"No escape when they manipulate ETFs in their favor. Just HODL and it will pop.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605955833","repostId":1186120067,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":605958578,"gmtCreate":1639104486244,"gmtModify":1639104486556,"author":{"id":"3585469772373012","authorId":"3585469772373012","name":"JCinvest","avatar":"https://static.tigerbbs.com/b448a34b681278065a05698ba3728bbb","vip":1,"crmLevel":9,"crmLevelSwitch":0,"idStr":"3585469772373012","authorIdStr":"3585469772373012"},"htmlText":"Yeah","listText":"Yeah","text":"Yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/605958578","repostId":1186120067,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":92,"commentSize":13,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186120067"}